Arbitration has become the forum of choice for resolving life sciences disputes, where technical complexity, confidentiality, and cross-border dynamics intersect. This session will explore the sector's distinct challenges, focusing on the critical interplay between liability and quantum. When collaborations or supply agreements break down, allegations of non-compliance with regulatory or technical specifications or failures to secure approvals often underpin termination. These disputes raise intricate questions around causation, counterfactuals, and valuation.
The panel will examine how to address such issues and discuss methodologies for assessing reasonable royalties, lost profits, and negotiating damages within the particular economic and regulatory context of the life sciences industry. Beyond traditional breaches, new risks are emerging. The discussion will also consider how trade-secret disputes and AI-driven R&D are giving rise to novel liability and evidentiary questions.
Featuring counsel, in-house specialists, and quantum experts, this panel will provide practical insights on how arbitrators and practitioners can navigate the intersection of science, commerce, and regulation that defines modern life sciences arbitration.